Utama › Kegagalan Ginjal › Arizona
Kajian klinikal Kegagalan Ginjal di Arizona
6 kajian untuk Kegagalan Ginjal sedang mencari peserta di lokasi di Arizona.
Bandar di Arizona
Teks kajian rasmi (Bahasa Inggeris)
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
- Arizona Clinical Trials - Chandler, Chandler
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 84 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07763418Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- AKDHC Medical, Glendale
- Kidney Disease Medical Group, Glendale
- AKDHC Medical, Phoenix
- dan 2 lagi
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05485961REgulatory T Cell Therapy to Achieve Immunosuppression REduction
- Mayo Clinic in Arizona, Phoenix
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 27 Apr 2026 · NCT06552169Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
- Southwest Kidney Institute, Phoenix
- AKDHC Medical Research Services, Phoenix
- AKDHC Center Tucson, Tucson
Mengambil peserta
Umur 18 hingga 84 · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06190717SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
- AKDHC Bullhead City, Bullhead City
- AKDHC Marana Surgery Center, Marana
- Arizona Kidney Disease & Hypertension Centers (AKDHC) Phoenix Surgery Center, Phoenix
- dan 1 lagi
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Feb 2026 · NCT06001827A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- AKDHC Medical Research Services, LLC, Phoenix
Mengambil peserta
Umur 18 hingga 90 · Semua jantina · Dikemas kini 22 Dis 2025 · NCT04671771Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.